1
Dominique P Bridon, Alan M Ezrin, Peter G Milner, Darren L Holmes, Karen Thibaudeau: Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components. ConjuChem Biotechnologies, Jones Day, August 14, 2007: US07256253 (17 worldwide citation)

A secretin or secretin derivative protected against peptidase activity. The secretin or derivative comprises a peptidic sequence and a reactive group selected from the group consisting of succinimidyl and maleimido groups capable of reacting with an amino group, hydroxyl group or thiol group on a bl ...


2
Bridon Dominique P, Bousquet Gagnon Nathalie, Huang Xicai, Quraishi Omar: Compounds for specific viral target. Conjuchem Biotechnologies, Bridon Dominique P, Bousquet Gagnon Nathalie, Huang Xicai, Quraishi Omar, LECLAIRE France, November 17, 2005: WO/2005/108418 (17 worldwide citation)

The present application relates to a compound having a formula (I): B-R1-R2-M wherein B is a binding element for recognizing and binding a target; R1 is a first group of atoms for reacting with a functionality of the target so as to form a covalent bond with the target; R2 is a second group of atoms ...


3
Dominique P Bridon, Nissab Boudjellab, Roger Léger, Martin Robitaille, Lucie Jetté, Corinne Benquet: Long lasting growth hormone releasing factor derivatives. ConjuChem Biotechnologies, Jones Day, September 11, 2007: US07268113 (11 worldwide citation)

This invention relates to growth hormone releasing factor (GRF) derivatives. In particular, this invention relates to GRF peptide derivatives having an extended in vivo half-life, for promoting the endogenous production or release of growth hormone in humans and animals.


4
Nathalie Bousquet Gagnon, Omar Quraishi, Dominique P Bridon: Method for purification of albumin conjugates. ConjuChem Biotechnologies, Jones Day, December 11, 2007: US07307148 (10 worldwide citation)

The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the suppo ...


5
John W Erickson, Dominique P Bridon, Martin Robitaille, Grant A Krafft, Dong Xie, Elena Afonina, Jun Liang, Sandra DeMeyer: Long lasting fusion peptide inhibitors for HIV infection. Conjuchem Biotechnologies, Lando & Anastasi, June 22, 2010: US07741453 (9 worldwide citation)

The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), ...


6
Bousquet Gagnon Nathalie, Quraishi Omar, Bridon Dominique P: Method for the purification of albumin conjugates. Conjuchem Biotechnologies, Bousquet Gagnon Nathalie, Quraishi Omar, Bridon Dominique P, LECLAIRE France, November 3, 2005: WO/2005/103087 (9 worldwide citation)

A method for separating albumin conjugates from unconjugated albumin in a solution comprising albumin conjugates and unconjugated albumin by hydrophobic Interaction Chromatography (HIC). The solution is loaded onto the hydrophobic column equilibrated in aqueous buffer having a high salt content; app ...


7
Alexander Krantz, Wolin Huang, Arthur M Hanel, Darren L Holmes, Dominique P Bridon: Affinity markers for human serum albumin. ConjuChem Biotechnologies, Jones Day, January 23, 2007: US07166695 (8 worldwide citation)

Methods and compositions are provided for identifying compounds having affinity or complementarity to a target molecule. Compounds according to the invention may be described by the formula E-Ca—R—Cb-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, Ca and Cb are connector gr ...


8
Quraishi Omar: Process for the production of preformed conjugates of albumin and a therapeutic agent. Conjuchem Biotechnologies, Quraishi Omar, BERESKIN 40 King Street West 40th Floor Suite 4000 Toronto Ontario M5H 3Y2, June 28, 2007: WO/2007/071068 (8 worldwide citation)

The present invention provides processes for the production of preformed albumin conjugates. In particular, the invention provides processes for the in-vitro conjugation of a therapeutic compound to recombinant albumin, wherein a therapeutic compound comprising a reactive group is contacted to recom ...


9
Bridon Dominique P, Castaigne Jean Paul, Thibodeau Karen: Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin. Conjuchem Biotechnologies, Bridon Dominique P, Castaigne Jean Paul, Thibodeau Karen, BERESKIN 40 King Street West 40th Floor Suite 4000 Toronto Ontario M5H 3Y2, May 18, 2007: WO/2007/053946 (6 worldwide citation)

The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provid ...


10
Dominique P Bridon, Roger Leger, Xicai Huang, Karen Thibaudeau, Martin Robitaille, Peter G Milner: Anti-obesity agents. Conjuchem Biotechnologies, Lando & Anastasi, October 13, 2009: US07601691 (5 worldwide citation)

The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a con ...